TD Cowen raised the firm’s price target on Twist Bioscience (TWST) to $43 from $32 and keeps a Buy rating on the shares. The firm adjusted price targets in the diagnostic tools group group as part of a Q4 preview. Investor sentiment continues to inflect upward with 2026 guidance updates “key for positioning within the sector recovery,” the analyst tells investors in a research note. TD is most positive on stocks “with clear multi-year frameworks and multiple avenues for upside to derisked growth assumptions.”
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TWST:
- Twist Bioscience price target raised to $42 from $34 at Evercore ISI
- Cathie Wood Wraps Up 2025 with New Biotech Buys — Here’s What It Sold
- Cathie Wood Closes Out 2025 with a Rocket Lab (RKLB) Trim and Fresh Biotech Bets
- Twist Bioscience price target raised to $39 from $37 at Barclays
- Private Markets: Prediction market platform Kalshi secures $300M